There is an increased risk of serious cardiac arrhythmias and heart failure in patients taking ibrutinib. This is more common in elderly patients, patients with pre-existing heart problems or who are at risk for heart problems. This is according to the studies of the ibrutinib manufacturer.
Ibrutinib is used to treat types of leukemia and lymphoma.
It is recommended that cardiac function be monitored before and during treatment with ibrutinib. The dose should be adjusted in case of heart problems. In some cases, ibrutinib must be discontinued.
Side Effects Center Lareb has also received some reports of heart problems with ibrutinib.
Read the full report from the Medicines Evaluation Board here.
